This developing technology will allow patients to regrow tissues in their own body, possibly revolutionizing the transplant market.
Morphoceuticals, Inc.’s mission is to establish a basis for limb regeneration and discovery of novel regenerative interventions.
Morphoceuticals originated from the work of co-founders Dr. Michael Levin, PhD
and Dr. David Kaplan, PhD at the Allen Discovery Center at Tufts University. Our focus is on a revolutionary understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation. We use bioelectric dynamics to change developmental patterning and spur regeneration in organisms that do not regenerate tissues or organs.
The team is building a next-generation AI platform to map top-down control of pattern regulation. Levin’s lab has been able to cause limb regeneration in a variety of animals. Morphoceuticals is initiating research to translate this progress from lower animals to mammals.
The frontier of regenerative medicine is a promising market that, estimated at $23 billion in 2018, is expected to increase to $150 billion by 2026.
We are here to help answer any questions you might have.